NCT04348747View on ClinicalTrials.gov

Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 19, 2022

Primary Completion Date

December 15, 2025

Study Completion Date

December 15, 2026

Conditions

Anatomic Stage IV Breast Cancer AJCC v8Metastatic Malignant Neoplasm in the BrainMetastatic Triple-Negative Breast CarcinomaPrognostic Stage IV Breast Cancer AJCC v8

Interventions

BIOLOGICAL

Anti-HER2/HER3 Dendritic Cell Vaccine

Given ID

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (3)

14263

RECRUITING

Roswell Park Cancer Institute, Buffalo

22903

RECRUITING

University of Virginia Comprehensive Cancer Center, Charlottesville

33612

RECRUITING

Moffitt Cancer Center, Tampa

All Listed Sponsors

collaborator

United States Department of Defense

FED

lead

Roswell Park Cancer Institute

OTHER